MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 2, 2005; DOI: 10.1124/mol.105.012773


0026-895X/05/6803-737-746$20.00
Mol Pharmacol 68:737-746, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.012773v1
68/3/737    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCallum, S. E.
Right arrow Articles by Quik, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCallum, S. E.
Right arrow Articles by Quik, M.

Decrease in {alpha}3*/{alpha}6* Nicotinic Receptors but Not Nicotine-Evoked Dopamine Release in Monkey Brain after Nigrostriatal Damage

Sarah E. McCallum, Neeraja Parameswaran, Tanuja Bordia, J. Michael McIntosh, Sharon R. Grady, and Maryka Quik

The Parkinson's Institute, Sunnyvale, California (S.E.M., N.P., T.B., M.Q.); Institute for Behavioral Genetics, University of Colorado, Denver, Colorado (S.R.G.); and Department of Biology and Psychiatry, University of Utah, Salt Lake City, Utah (J.M.M.)

Nicotinic acetylcholine receptors (nAChRs) are decreased in the striata of patients with Parkinson's disease (PD) or in experimental models after nigrostriatal damage. Because presynaptic nAChRs on striatal dopamine terminals mediate dopamine release, receptor loss may contribute to behavioral deficits in PD. The present experiments were done to determine whether nAChR function is affected by nigrostriatal damage in nonhuman primates, because this model shares many features with PD. Initial characterization of nicotine-evoked [3H]dopamine release from monkey striatal synaptosomes revealed that release was calcium-dependent and inhibited by selective nAChR antagonists. It is noteworthy that a greater proportion (~70%) of release was inhibited by the {alpha}3*/{alpha}6* antagonist {alpha}-conotoxinMII ({alpha}-CtxMII) compared with rodents. Monkeys were lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and [3H]dopamine release, dopamine transporter, and nAChRs were measured. As anticipated, lesioning decreased the transporter and {alpha}3*/{alpha}6* nAChRs in caudate and putamen. In contrast, {alpha}3*/{alpha}6* nAChR-evoked [3H]dopamine release was reduced in caudate but not putamen, demonstrating a dissociation between nAChR sites and function. A different pattern was observed in the mesolimbic dopamine system. Dopamine transporter levels in nucleus accumbens were not reduced after MPTP, as expected; however, there was a 50% decline in {alpha}3*/{alpha}6* nAChR sites with no decrease in {alpha}3*/{alpha}6* receptor-evoked dopamine release. No declines in {alpha}-CtxMII-resistant nAChR ({alpha}4*) binding or nicotine-evoked release were observed in any region. These results show a selective preservation of {alpha}3*/{alpha}6* nAChR-mediated function in the nigrostriatal and mesolimbic dopamine systems after nigrostriatal damage. Maintenance of function in putamen, a region with a selective loss of dopaminergic terminals, may be important in PD.


Received March 11, 2005; accepted June 1, 2005

Address correspondence to: Dr. Maryka Quik, The Parkinson's Institute, 1170 Morse Ave, Sunnyvale, CA 94089-1605. E-mail: mquik{at}parkinsonsinstitute.org




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. T. O'Leary, N. Parameswaran, L. C. Johnston, J. M. McIntosh, D. A. Di Monte, and M. Quik
Paraquat Exposure Reduces Nicotinic Receptor-Evoked Dopamine Release in Monkey Striatum
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 124 - 129.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. O'Leary, N. Parameswaran, J. M. McIntosh, and M. Quik
Cotinine Selectively Activates a Subpopulation of {alpha}3/{alpha}6{beta}2 Nicotinic Receptors in Monkey Striatum
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 646 - 654.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. C. Perry, D. Mao, A. B. Gold, J. M. McIntosh, J. C. Pezzullo, and K. J. Kellar
Chronic Nicotine Differentially Regulates {alpha}6- and beta3-Containing Nicotinic Cholinergic Receptors in Rat Brain
J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 306 - 315.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
O. Salminen, J. A. Drapeau, J. M. McIntosh, A. C. Collins, M. J. Marks, and S. R. Grady
Pharmacology of {alpha}-Conotoxin MII-Sensitive Subtypes of Nicotinic Acetylcholine Receptors Isolated by Breeding of Null Mutant Mice
Mol. Pharmacol., June 1, 2007; 71(6): 1563 - 1571.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik
Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. E. McCallum, N. Parameswaran, T. Bordia, H. Fan, J. M. McIntosh, and M. Quik
Differential Regulation of Mesolimbic {alpha}3/{alpha}6beta2 and {alpha}4beta2 Nicotinic Acetylcholine Receptor Sites and Function after Long-Term Oral Nicotine to Monkeys
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 381 - 388.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
M. Quik, L. Chen, N. Parameswaran, X. Xie, J. W. Langston, and S. E. McCallum
Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
J. Neurosci., April 26, 2006; 26(17): 4681 - 4689.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. Quik and J. M. McIntosh
Striatal {alpha}6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 481 - 489.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics